Mon Top 3 Antidépresseurs

💊 Patreon:   / monsieurza   💊 Free resources from the video: Which SSRI for whom? (full grid): https://files.catbox.moe/by99nw.png Sigma-1 receptor (functions): https://files.catbox.moe/wzieqi.png Action of molecules on the sigma-1 receptor: https://files.catbox.moe/7vslvd.png Citalopram enantiomers: https://files.catbox.moe/pp7u2j.png 💊 Sources used in the video: GSK / Study 329: Le Noury et al., BMJ, 2015, "Restoring Study 329..." [Independent reanalysis of S329 raw data. Lack of paroxetine efficacy in young patients and hidden increased suicidal risk in the original publication] Kondro & Sibbald, CMAJ, 2004, "Drug company experts advised staff to withhold data about SSRI use in children": https://www.cmaj.ca/content/170/5/783 [Article that made public the existence of the document below] Internal SmithKline Beecham document, October 1998, "Seroxat/Paxil Adolescent Depression: Position piece on the phase III clinical studies": https://web.archive.org/web/200710101... [Confidential memo with the TARGET section and the "commercially unacceptable" formulation] U.S. Department of Justice, 2012, https://www.justice.gov/opa/pr/glaxos... [Official press release of the 3 billion dollar settlement against GSK] Pharmacological sources: Cipriani et al., The Lancet, 2018, "Comparative efficacy and acceptability of 21 antidepressant drugs..." [Reference network meta-analysis placing escitalopram among the few molecules simultaneously in the top tier for both efficacy and tolerability] Sánchez et al., Int Clin Psychopharmacol, 2014, "A comparative review of escitalopram, paroxetine, and sertraline..." [Comparative review of 3 SSRIs and their pharmacological and clinical profiles] Gerlach et al., Eur Child Adolesc Psychiatry, 2016, "Therapeutic drug monitoring..." [Pharmacokinetic data on SSRIs, including comparative half-lives and the role of CYP2D6] March et al. (TADS Team), JAMA, 2004, "Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression..." [Pivotal study demonstrating fluoxetine's efficacy in pediatric depression, basis for its French marketing authorization from age 8] Ye et al., J Med Chem, 2022, "Small molecules selectively targeting sigma-1 receptor..." [Pharmacology of the sigma-1 receptor and its role in mood regulation] Hayashi & Su, Cell, 2007, "Sigma-1 receptor chaperones at the ER-mitochondrion interface..." [Cellular functions of the sigma-1 receptor] Marjoribanks et al., Cochrane, 2013, "Selective serotonin reuptake inhibitors for premenstrual syndrome" [SSRI efficacy in PMDD + luteal phase dosing] Funk & Bostwick, Ann Pharmacother, 2013, "A comparison of the risk of QT prolongation among SSRIs" [Dose-dependent specificity of escitalopram and citalopram on QT prolongation] HIA Bégin, "CYP2D6: un gène hautement polymorphe" [Distribution of CYP2D6 phenotypes by origin, source of the table shown in the video] 💊 Related videos: "Antidepressants: Stop Lumping Them Together":    • Antidépresseurs : Arrêtez de tout confondre   "Éloge de la Ritaline":    • Éloge de la Ritaline   (No subtitles) 💊 Further reading: Peter Kramer, Listening to Prozac, Viking Press, 1993. [Foundational work questioning antidepressant prescription beyond strict clinical indication] David Healy, Let Them Eat Prozac, NYU Press, 2004. [Investigation into industrial practices around SSRIs, including the GSK case and pediatric trials] J. Moncrieff, The Myth of the Chemical Cure, Palgrave Macmillan, 2008. [Critique of the disease-centered model in pharmacological psychiatry by the co-founder of the Critical Psychiatry Network] Jureidini & McHenry, The Illusion of Evidence-Based Medicine, Wakefield Press, 2020. [How the pharmaceutical industry transformed evidence-based medicine into a marketing tool] French Law no. 2002-303 of 4 March 2002 on patients' rights and the quality of the health system. [Foundational French law on informed consent, art. L. 1111-2 of the Public Health Code, "loi Kouchner"] 💊 Chapters: 0:00 Introduction 1:37 Back to the tricyclics 4:40 Paroxetine, the unfinished SSRI 6:10 A non-linear withdrawal 8:52 GSK 2012 and Study 329 13:25 Fluoxetine: the old patriarch 15:02 Atypical half-life and absence of withdrawal 16:40 Activating profile and pediatric approval 20:53 Side note: CYP2D6 genotyping 23:16 Sertraline: the safe bet 24:13 Dopaminergic profile and sigma-1 antagonism 26:05 French approval for PTSD and PMDD 29:02 Digestive effects and activation syndrome 32:40 Escitalopram: the culmination of the SSRI project 33:28 Citalopram and its enantiomers 35:12 Maximum selectivity and the anxiety spectrum 38:33 Efficacy-tolerability ratio 39:06 QT prolongation and psychomotor slowing 41:00 The grid: Which SSRI for whom? 41:37 By clinical profile 43:41 By side effect to avoid 46:00 Conclusion